Vivos Inc. announced the initiation of its first human clinical trial for RadioGel Precision Radionuclide Therapy in India, marking a significant step in advancing cancer therapies. The trial commenced with the successful treatment of five patients diagnosed with cancerous lymph nodes. This initial phase focuses on demonstrating the therapy's safety.
Imaging confirmed the precise placement of the RadioGel treatment, and all five patients are reported to be recovering well without complications. The protocol for this trial in India closely aligns with the design for Vivos's planned study at the Mayo Clinic in the United States, with results intended to support FDA submissions.
The study has received regulatory approval to expand to 30 patients, targeting cancerous nodes throughout the body, which will enable broader therapeutic applications. This dual-track international strategy is designed to accelerate the global introduction of Vivos's cutting-edge cancer therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.